Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of ASP Isotopes Inc. (NASDAQ: ASPI) breached their fiduciary duties to shareholders. If you currently own ASP Isotopes stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-appr ...

This Production Update reports operational progress since April 2025, following bridge loan funding provided by ASP Isotopes Inc. (“ASPI”) (prior to the completion of ASPI’s acquisition of Renergen), and highlights measurable improvements in drilling execution, gas production, subsurface confidence, and commercial readiness since ASPI involvement. Key highlights include: Investment has augmented existing operational capacity. Management estimates the plant is now processing approximately 60% more gas as a r ...

Group 1 - The core viewpoint of the report emphasizes the potential of Novartis' Pluvicto in the nuclear medicine sector, particularly in the context of Radioligand Therapy (RDC), which is expected to drive growth in the nuclear medicine industry [4][15][26] - The report highlights that the nuclear medicine market in China is projected to reach 26 billion yuan by 2030, with significant growth potential driven by policy support and technological advancements [16][20] - The report identifies key companies to watch, including Dongcheng Pharmaceutical, which has a leading integrated drug innovation platform, and ASP Isotopes Inc., which focuses on high-value isotope production [4][32][37] Group 2 - The report provides a market review for the week of January 19-23, 2026, noting that the CITIC Pharmaceutical Index fell by 0.4%, while the pharmaceutical sector has seen a year-to-date increase of 6.5% [3][40] - The report indicates that the top-performing stocks in the pharmaceutical sector during this week included Changyao Holdings (+70.4%) and Hualan Biological Engineering (+32.2%) [5][55] - The report discusses the performance of various sub-sectors within the pharmaceutical industry, with pharmaceutical distribution and retail showing positive trends, while innovative drugs and CXO sectors lagged [5][43][66]

ASP Isotopes (ASPI) stock soared on Jan. 9 after completing a key acquisition of Renergen Limited, representing a pivotal milestone in the company’s growth trajectory. This strategic combination merges ASPI’s advanced enrichment tech with Renergen’s substantial helium and natural gas production assets, particularly the Virginia Gas Project in South Africa. More News from Barchart Despite this rally, ASPI stock remains down some 45% versus its 52-week high. www.barchart.com Why the Renergen Deal Matte ...

Company Overview - ASP Isotopes Inc. (ASPI) has successfully closed its acquisition of Renergen Limited, which enhances its capabilities in isotope enrichment and expands its portfolio in the energy sector [1][3]. - The merger combines ASP Isotopes' advanced enrichment technologies with Renergen's helium and natural gas assets, particularly the Virginia Gas Project in South Africa [1][2]. Strategic Goals - The combined entity aims to become a leading global supplier of critical materials for high-growth sectors such as semiconductors, quantum computing, and clean energy [2]. - A significant aspect of the deal is Renergen's access to approximately $750 million in committed debt funding from the U.S. International Development Finance Corporation (DFC) to boost helium production capacity [2]. Market Position - ASP Isotopes does not directly mine rare earth elements but focuses on the production and enrichment of stable isotopes that are part of the broader strategic materials universe, including elements related to rare earths [3].

Core Insights - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by approximately 200 points on Friday [1] Company Highlights - CG Oncology Inc (NASDAQ:CGON) saw its shares rise by 21.8% to $51.05 after announcing an expedited timeline for topline data from the Phase 3 PIVOT-006 clinical trial, now expected in the first half of 2026 [1][2] - Rich Sparkle Holdings Ltd (NASDAQ:ANPA) surged 113.6% to $51.70 following a $39 million offering of 3 million ordinary shares at $13 per share [3] - NovaBay Pharmaceuticals Inc (NYSE:NBY) increased by 34.4% to $12.81 [3] - Quanterix Corp (NASDAQ:QTRX) gained 29.3% to $8.42 after naming Everett Cunningham as President and CEO, effective January 19 [3] - MoonLake Immunotherapeutics (NASDAQ:MLTX) rose 21.7% to $17.45 after receiving FDA feedback on its clinical evidence strategy for Sonelokimab in Hidradenitis Suppurativa [3] - Enliven Therapeutics Inc (NASDAQ:ELVN) increased by 21.5% to $28.24, sharing positive initial data from its Phase 1b ENABLE trial for ELVN-001 in chronic myeloid leukemia [3] - Aeva Technologies Inc (NASDAQ:AEVA) surged 21.2% to $20.47 [3] - Loandepot Inc (NYSE:LDI) rose 20.1% to $2.93 [3] - ASP Isotopes Inc (NASDAQ:ASPI) increased by 19.7% to $7.71 [3] - Allogene Therapeutics Inc (NASDAQ:ALLO) gained 19.5% to $1.78 [3] - Opendoor Technologies Inc (NASDAQ:OPEN) rose 19.2% to $7.67 following a new housing market proposal by President Donald Trump [3] - Liquidia Corp (NASDAQ:LQDA) jumped 14% to $36.22 after announcing preliminary full-year 2025 YUTREPIA net sales [3] - Vistra Corp (NYSE:VST) gained 13.1% to $170.34 after entering into 20-year power purchase agreements for zero-carbon nuclear energy to support Meta's operations [3] - Oklo Inc (NYSE:OKLO) rose 12.6% to $109.95 after announcing an agreement with Meta for a 1.2 gigawatt power campus [3] - Applied Digital Corp (NASDAQ:APLD) surged 11.8% to $35.72, reporting strong second-quarter results and advanced talks with a new hyperscaler tenant [3] - AST SpaceMobile Inc (NASDAQ:ASTS) gained 10% to $99.65 [3] - SanDisk Corp (NASDAQ:SNDK) increased by 9.6% to $366.93 [3] - Mirion Technologies Inc (NYSE:MIR) rose 9.5% to $26.56 [3] - TTM Technologies Inc (NASDAQ:TTMI) gained 9.1% to $72.94 [3] - SoundHound AI Inc (NASDAQ:SOUN) rose 8.5% to $11.96 [3] - Kratos Defense & Security Solutions Inc (NASDAQ:KTOS) gained 8.3% to $112.64, with B. Riley Securities maintaining a Buy rating and raising the price target from $105 to $128 [3]

Industry Overview - Nuclear energy is transitioning from being viewed as the "black sheep" of the power sector to the "gold standard" for clean energy due to increasing electricity demands from AI data centers and electric vehicles [1] - Unlike solar and wind energy, nuclear energy provides reliable "baseload" power, operating continuously and emitting zero carbon [2] Company Focus: ASP Isotopes (ASPI) - ASP Isotopes (ASPI) is identified as a high-risk, high-reward investment opportunity, focusing on the enrichment process of uranium fuel [2] - The company employs a proprietary method called Aerodynamic Separation for uranium enrichment, which is efficient and cost-effective [3] - ASPI is positioning itself as a primary supplier of High-Assay Low-Enriched Uranium (HALEU), essential for next-generation small modular reactors (SMRs), amid a global shortage [4] Financial Position and Growth - ASP recently raised over $72 million to establish an enrichment facility in South Africa and acquired Renergen Limited, diversifying into helium production for a more stable revenue stream [5] - In the first nine months of 2025, ASP reported a loss of nearly $100 million, ending Q3 with $113 million in cash, indicating a potential need for additional capital [5] - Analysts have a "Strong Buy" recommendation for ASPI, with a mean stock price target of $12, significantly above the current price of $6.31 [6]

Combined Company Expected to Become a Global Critical Materials Provider Focused on High-Growth Industries in Isotope and Helium Markets Renergen Expected to Benefit from $750 million of Committed Debt Funding from the U.S. government's Development Finance Corporation (U.S. DFC) and Other Lenders to Expand Helium Plant Production Capacity Combined Company Expected to Target Cross-Sector Applications in Semiconductors, Quantum Computing, and Clean Energy DALLAS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes ...

Core Viewpoint - Kahn Swick & Foti, LLC has initiated an investigation into ASP Isotopes, Inc. following allegations of misleading investors regarding its nuclear fuel technologies and other operational claims [1][2]. Company Overview - ASP Isotopes is a development stage advanced materials company focused on the production, enrichment, and sale of isotopes [2]. - The company has faced scrutiny for its claims about the viability of its nuclear fuel technologies, particularly regarding its High Assay Low-Enriched Uranium (HALEU) facilities [2]. Allegations and Legal Actions - A report by Fuzzy Panda Research accused ASP Isotopes of misleading investors, stating that the company had never tested its technology on uranium and that its cost estimates and timelines were misleading [2]. - Following these allegations, ASP Isotopes and certain executives were sued in a securities class action lawsuit for failing to disclose material information, violating federal securities laws [3]. - The court has denied the company's motion to dismiss part of the case, allowing the lawsuit to proceed [3]. Investigation Focus - Kahn Swick & Foti's investigation is centered on whether ASP's officers and/or directors breached their fiduciary duties to shareholders or violated state or federal laws [3].

Core Insights - ASP Isotopes has received all necessary regulatory approvals for the acquisition of Renergen, allowing the scheme to proceed [1][2] - The acquisition aims to create a global leader in the production of critical materials, including helium and isotopically enriched gases, with significant synergies expected from 2026 [3][4] - Positive operational progress has been reported at Renergen's Virginia Gas Project, with a production update anticipated by the end of January 2026 [4] Company Overview - ASP Isotopes is focused on developing technology for isotope production, utilizing proprietary Aerodynamic Separation Process technology [5] - The company plans to enrich isotopes for various sectors, including healthcare, technology, and nuclear energy [5][6] - There is a growing demand for specific isotopes for applications in quantum computing and green energy [6] Acquisition Details - Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each share held, as part of the acquisition scheme [1] - The implementation of the scheme will commence upon receipt of a compliance certificate from the South African Takeover Regulation Panel, expected around December 18, 2025 [2] - The merger is expected to create a vertically and horizontally integrated supply chain with substantial geographic and customer overlap [3]